Tavotek Biotherapeutics Announces Completion of Round B Funding with $ 35 Million


LOWER GWYNEDD, Penn., November 18, 2021 / PRNewswire / – Tavotek Biotherapeutics, a fast growing biotech company, announces that it has raised $ 35 million in funding from Round B. CS Capital, a leading private equity fund manager in China, led this round table followed by Fontus Capital. This round of funding will be used to accelerate the phase 1 clinical development of several antibody-based drugs which will begin in early 2022. Future antibody-based drugs have been developed by the company on the basis of its platform. form of TavoPrecise antibody for various disorders related to the immune system. In addition, the funding will also be used to accelerate the CMC and IND development of several other oncology pipelines and the development of the Company’s multicyclic intracellular peptide (MIP) programs.

Tavotek Biotherapeutics, established in early 2019, is committed to using innovation to improve the well-being of patients with unmet medical needs. The company has two R&D centers: one in Lower Gwynedd, Pennsylvania and another in Suzhou, China. Core team members have decades of successful drug development experience at multinational pharmaceutical companies (Johnson & Johnson, Abbott / Abbvie, GlaxoSmithKline and Eli Lilly) which include many successful drugs with annual sales of over a billion dollars.

Tavotek’s research platforms are based on three disruptive technologies: TavoSelect (an innovative phage display library that generates full-length, single-domain conformational selective human antibodies); TavoPrecise (a differentiated engineering platform for next-generation tissue-specific biologics); and TavoMIP (a multicyclic peptide platform that makes non-drug targets more accessible). With the new capital injection, Tavotek is developing new biologics targeting oncology and autoimmune diseases for patients. The company plans to introduce several innovative antibodies into human clinical trials in 2022.

About Tavotek

Tavotek is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for patients with debilitating diseases with significant unmet medical needs. Tavotek has a rich portfolio of product candidates at various stages of development for cancer, autoimmune diseases and inflammatory diseases. For more information, please visit www.tavotek.com.

Contact Tavotek:

Vicky wu, External Affairs
E-mail: [email protected]

Isa Fung, Investors and Media
E-mail: [email protected]

SOURCE Tavotek Biotherapeutics

Source link


Comments are closed.